Valuation: Cytosorbents Corporation

Market Cap 16.51M 14.79M 13.64M 12.35M 23.09M 1.57B 23.46M 163M 64.94M 823M 61.97M 60.65M 2.61B P/E 2026 *
-1.19x
P/E 2027 * -5.82x
Enterprise Value 16.51M 14.79M 13.64M 12.35M 23.09M 1.57B 23.46M 163M 64.94M 823M 61.97M 60.65M 2.61B EV / Sales 2026 *
0.42x
EV / Sales 2027 * 0.37x
Free-Float
83.75%
Yield 2026 *
-
Yield 2027 * -
1 day-16.03%
1 week-26.79%
Current month+12.82%
1 month+10.00%
3 months-37.85%
6 months-65.39%
Current year-65.58%
1 week 4.1
Extreme 4.0978
5.96
1 month 2.84
Extreme 2.8402
6.96
Current year 2.84
Extreme 2.8402
16.89
1 year 2.84
Extreme 2.8402
17
3 years 2.84
Extreme 2.8402
43
5 years 2.84
Extreme 2.8402
132.8
10 years 2.84
Extreme 2.8402
299
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2008
Director of Finance/CFO 62 14/08/2024
President 68 28/04/2020
Director TitleAgeSince
Director/Board Member 77 25/07/2011
Director/Board Member 55 01/01/2009
Director/Board Member 65 13/11/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Buy

Chief Executive Officer

3,774 0.0060%
15/09/26 Buy

Director

2,500 0.0040%
14/09/26 Buy

Chairperson

2,073 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-16.03%-26.79%-71.86%-84.83% 16.51M
+0.71%+4.82%+27.02%+63.36% 260B
+1.24%+3.15%+10.73%+28.03% 165B
+1.03%+1.11%-16.52%+73.61% 154B
+0.61%-7.22%-57.44%-14.71% 61.49B
+2.90%+4.83%+14.21%+51.44% 52.9B
+0.70%+2.71%-13.09%-6.29% 52.84B
-2.35%-3.79%+8.26%+63.10% 51.46B
-0.18%+4.18%+26.50%+79.06% 51.16B
+0.67%+5.37%+39.77%+102.82% 46.85B
Average -1.23%+1.00%-3.24%+35.56% 89.57B
Weighted average by Cap. +0.46%+1.41%+7.18%+51.40%

Financials

2026 *2027 *
Net sales 38.88M 34.83M 32.13M 29.08M 54.37M 3.7B 55.25M 383M 153M 1.94B 146M 143M 6.14B 44.16M 39.56M 36.49M 33.02M 61.75M 4.21B 62.75M 435M 174M 2.2B 166M 162M 6.97B
Net income -13.91M -12.46M -11.49M -10.4M -19.45M -1.32B -19.77M -137M -54.71M -693M -52.2M -51.09M -2.2B -2.77M -2.48M -2.29M -2.07M -3.88M -264M -3.94M -27.32M -10.9M -138M -10.4M -10.18M -438M
Net Debt - -
Projected Income Statement - Annual - Cytosorbents Corporation
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
30/10/26 $4.400 -16.03% 48,275
28/10/26 $5.240 +8.04% 23,075
27/10/26 $4.850 +8.50% 41,323
26/10/26 $4.470 -15.18% 44,186
23/10/26 $5.270 -12.31% 43,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cytosorbents Corporation
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.240USD
Average target price
47.50USD
Spread / Average Target
+806.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cytosorbents Corporation
  1. Stock Market
  2. Stocks
  3. CTSO Stock